Boston Therapeutics, Inc. OTCQB: BTHE , headquartered in Lawrence, MA, is a leader in the field of designing drugs using complex carbohydrates. The Company s product pipeline is focused on developing and commercializing therapeutic molecules for diabetes, including: BTI , a non systemic chewable compound designed to reduce post meal glucose elevation IPOXYN, an injectable anti necrosis drug specifically designed to treat lower limb ischemia and SUGARDOWN R , an OTC dietary supplement designed to lower post meal sugar spike. More information on BTHE is available at www.bostonti.com.
Quote | Boston Therapeutics Inc (OTCMKTS:BTHE)
Last: | $0.01 |
---|---|
Change Percent: | 0.0% |
Open: | $0.00915 |
Close: | $0.01 |
High: | $0.0119 |
Low: | $0.0091 |
Volume: | 105,242 |
Last Trade Date Time: | 11/12/2021 04:54:33 pm |
News | Boston Therapeutics Inc (OTCMKTS:BTHE)
Post the recent reverse merger between Nanomix and Boston Therapeutics (OTCPK:BTHE), Nanomix announces the completion of its name change from Nanomix, Inc. to Nanomix Corporation and its ticker symbol from “BTHE” to “NNMX”. Company’s common shares ...
LAWRENCE, Mass., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter trial. With the recent inclusion of Miami Dade Medical Research Institute in June and IOWA Diabet...
Message Board Posts | Boston Therapeutics Inc (OTCMKTS:BTHE)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Boston Therapeutics Inc Company Name:
BTHE Stock Symbol:
OTCMKTS Market:
Boston Therapeutics Inc Website:
LAWRENCE, Mass., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics (OTCQB:BTHE) is again pleased to announce full enrollment of the BTI320 Ph 2 double-blind, placebo-controlled, multicenter trial. With the recent inclusion of Miami Dade Medical Research Institute in June and IOWA Diabet...
LAWRENCE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Boston Therapeutics Inc. (the “ Company ” or “ BTI ”) (OTCQB:BTHE), an innovator in the design, development and commercialization of novel therapeutics as an adjunct therapy for diabetes, launches the initial sal...